TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
GLUE

Monte Rosa Therapeutics Inc

Healthcare · Biotechnology · —

11.90$ -5.6% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GLUE
Line item 2019 2020 2021 2022 2023 2024 2025
– +345.1% +641.9% -6.5% -11.3% +44.4% +2.3%
– +346.7% +699.9% -20.9% -14.4% +59.8% +4.2%
– +595.6% +729.9% -84.1% +133.3% +75.1% -42.1%
– +595.6% +729.9% -24.1% -11.6% +60.1% +1.3%
– +54.9% – – -93.4% -65.7% +2,559.0%
– – – – – – –
– +246.3% +166.6% +119.7% – – –
– +322.1% -80.8% +277.3% +75.4% +73.3% -0.1%
– +582.1% -43.2% +53.7% +82.2% +236.9% -59.1%
– – – – +1.1% +17.5% +18.4%
– +121.2% -7.2% +19.9% +41.8% +54.4% -79.4%
– – – -21.9% -34.0% +24.4% +4.5%
– – – – – – –
– +0.0% +5.8% +1.5% +8.8% +43.8% -11.3%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?